Cyclin-dependent kinase (CDK) 4/6 inhibition significantly prolongs progression-free survival (PFS) in patients with metastatic breast cancer (mBRCA) whose disease progresses on endocrine therapies. This activity will examine emerging evidence and best practices supporting the use of CDK4/6 inhibitors. This activity was originally presented as a webcast series on the following 4 dates: February ...
- Online Presentation
No expired programs found.